Memento Medicines, Curacle and MabTics’ global development partner for MMT-205 (formerly MT-103), launched with a $93 million Series A financing co-led by Forbion, RA Capital Management, and Avego BioScience Capital, with participation from Sanofi Ventures and Samsara BioCapital.

The financing will support IND-enabling studies and further development of MMT-205, a Tie2-activating and VEGF-inhibiting bispecific antibody for retinal diseases, with clinical trials expected to begin in 2027.